{"gene":"MICB","run_date":"2026-04-28T18:30:28","timeline":{"discoveries":[{"year":1999,"finding":"MICA and MICB are stress-induced antigens recognized by gamma delta T cells expressing Vdelta1 variable region, acting as tumor-associated antigens that trigger cytotoxic responses without peptide antigen constraints.","method":"T cell recognition assays using tumor-derived Vdelta1 gamma delta T cell lines and clones against autologous and heterologous tumor cells expressing MICA/B","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — functional cytotoxicity assays replicated across multiple tumor types and T cell clones from different tumors, high citation count indicating foundational study","pmids":["10359807"],"is_preprint":false},{"year":2001,"finding":"NKG2D homodimers form stable complexes with monomeric MICA in solution without requiring additional components; NKG2D also binds cell surface MICB; MICA glycosylation enhances but is not essential for complex formation; allelic variants of MICA show large differences in NKG2D binding associated with a single amino acid substitution at position 129 in the alpha2 domain.","method":"Solution binding assays (soluble NKG2D and MICA), cell surface binding with soluble NKG2D, allelic mutagenesis analysis","journal":"Immunogenetics","confidence":"High","confidence_rationale":"Tier 1 — reconstituted binding in solution plus functional validation with allelic variants, high citation count","pmids":["11491531"],"is_preprint":false},{"year":2006,"finding":"MICB is shed by metalloproteases from tumor cell surfaces in soluble form; cell-bound MICB causes downregulation of surface NKG2D on NK cells, whereas soluble MICB did not alter NKG2D expression on NK cells in vitro, suggesting shedding impairs tumor immunogenicity primarily by reducing NKG2D-ligand density on malignant cells.","method":"Metalloprotease inhibitor experiments, NK cell NKG2D expression assays by flow cytometry, ELISA for soluble MICB in patient sera","journal":"Human immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (biochemical shedding assays, flow cytometry, patient sera ELISA)","pmids":["16698441"],"is_preprint":false},{"year":2006,"finding":"NKG2D and MICB undergo bidirectional intercellular transfer at the cytotoxic NK cell immune synapse (cNK-IS); MICB on target cells induces NKG2D clustering at the central supramolecular activation cluster (cSMAC) surrounded by F-actin at the peripheral SMAC; membrane-connective structures at cNK-IS contain F-actin, perforin, and NKG2D; brief NK–MICB+ target cell interactions reduce NKG2D-dependent NK cytotoxicity.","method":"Live cell imaging, immunofluorescence microscopy, cytotoxicity assays with MICB-expressing target cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — direct imaging of protein transfer, functional consequence measured by cytotoxicity assay, multiple orthogonal methods","pmids":["16849432"],"is_preprint":false},{"year":2007,"finding":"HDAC inhibitor trichostatin A (TsA) increases MICA and MICB expression on leukemic cells by increasing histone H3 acetylation and decreasing HDAC1 association at MICA and MICB promoters, leading to enhanced NKG2D-mediated cytotoxicity against leukemic cells.","method":"Chromatin immunoprecipitation (ChIP) assay, flow cytometry, cytotoxicity assays","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP directly demonstrates chromatin remodeling at MICB promoter, linked to functional NK cytotoxicity outcome","pmids":["17625602"],"is_preprint":false},{"year":2007,"finding":"The MICB promoter is polymorphic; a 2-bp deletion near the CCAAT box (-70) and GC box (-86) dramatically reduces MICB transcriptional activity (18-fold decrease) by diminishing Sp1 transcriptional activation; the minimal MICB promoter contains NF-Y binding (CCAAT box) and Sp1/Sp3/Sp4 binding (GC box) elements.","method":"Luciferase reporter assays, promoter deletion analysis, electrophoretic mobility shift assay (EMSA), functional transcription analysis","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — in vitro transcriptional assays with mutagenesis and functional validation of specific transcription factor binding","pmids":["17557375"],"is_preprint":false},{"year":2008,"finding":"Knockdown of Dicer in human cells induces DNA damage and upregulates MICA and MICB expression; this upregulation is prevented by pharmacological or genetic inhibition of ATM kinase, ATR kinase, or Chk1, establishing that MICB upregulation following Dicer knockdown is mediated through the DNA damage response pathway.","method":"RNAi knockdown of Dicer, pharmacological inhibition (ATM, ATR, Chk1 inhibitors), genetic inhibition, flow cytometry/RT-PCR for MICA/B expression","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic and pharmacological perturbations establishing pathway placement of MICB regulation downstream of DNA damage response","pmids":["18644891"],"is_preprint":false},{"year":2008,"finding":"5-aza-2'-deoxycytidine (5-aza-dC) upregulates MICB expression through promoter DNA demethylation combined with DNA damage; ATM kinase inhibition partially prevents this upregulation, indicating that both DNA demethylation and ATM-mediated DNA damage signaling contribute to MICB induction.","method":"Bisulfite sequencing for DNA methylation, pharmacological ATM inhibition, RT-PCR/flow cytometry for MICB expression","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — two orthogonal mechanisms identified (methylation + DNA damage), single lab","pmids":["18395517"],"is_preprint":false},{"year":2009,"finding":"MicroRNAs from diverse herpesviruses (HCMV, KSHV, EBV) directly target MICB mRNA at different but adjacent sites in its 3'UTR to repress MICB expression and enable NK cell evasion; despite lacking sequence homology, these viral miRNAs are functionally conserved in targeting MICB during authentic viral infection.","method":"Reporter assays with MICB 3'UTR, miRNA mimic/inhibitor experiments, authentic viral infection, NK cell cytotoxicity assays","journal":"Cell host & microbe","confidence":"High","confidence_rationale":"Tier 1-2 — reconstituted 3'UTR targeting demonstrated with mutagenesis, validated in authentic viral infection, multiple virus species, high citation count","pmids":["19380116"],"is_preprint":false},{"year":2010,"finding":"Crystal structure of HCMV UL16 in complex with MICB at 1.8 Å resolution reveals that UL16 uses a three-stranded beta-sheet to engage the alpha-helical surface of the MICB MHC class I-like platform domain, mimicking the NKG2D binding mode; UL16 binds MICB, ULBP1, and ULBP2 with nanomolar affinity (12–66 nM); binding requires glutamine at position 169 of MICB, and an arginine at this position (as in MICA or ULBP3) causes steric clashes preventing UL16 binding.","method":"X-ray crystallography (1.8 Å), surface plasmon resonance, mutagenesis","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with SPR affinity measurements and mutagenesis confirming binding determinants","pmids":["20090832"],"is_preprint":false},{"year":2011,"finding":"HHV-7 U21 immunoevasin binds to NK-activating ligands MICA and MICB and downregulates their surface expression, resulting in reduced NK-mediated cytotoxicity; this is mechanistically distinct from U21's known downregulation of class I MHC.","method":"Flow cytometry for MICB/MICA surface expression in U21-expressing cells, NK cytotoxicity assays","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding and surface downregulation measured with functional NK cytotoxicity readout, single lab","pmids":["22102813"],"is_preprint":false},{"year":2012,"finding":"miR-10b directly binds to the 3'UTR of MICB mRNA and downregulates MICB surface expression; antagonizing miR-10b enhanced NKG2D-mediated NK cell killing of tumor cells in vitro and reduced tumor growth in vivo; overexpression of miR-10b impaired tumor cell elimination through MICB downregulation.","method":"3'UTR reporter assays, miRNA mimic/inhibitor, flow cytometry for MICB surface expression, in vitro and in vivo NK cytotoxicity assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 — 3'UTR targeting validated with reporters, functional NK killing confirmed in vitro and in vivo, multiple orthogonal methods","pmids":["22915757"],"is_preprint":false},{"year":2013,"finding":"ADAM15 mediates MICB ectodomain shedding in pancreatic cancer cells; knockdown of ADAM15 increases cell surface MICB and reduces soluble MICB in conditioned media; gemcitabine suppresses ADAM15 expression, leading to decreased MICB shedding and increased surface MICB without altering MICB mRNA levels.","method":"siRNA knockdown of ADAM15, ELISA for soluble MICB, flow cytometry for surface MICB, RT-PCR for mRNA levels, immunohistochemistry on patient tissue","journal":"Molecular medicine reports","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA knockdown with multiple readouts linking specific metalloprotease to MICB shedding mechanism, single lab","pmids":["23314034"],"is_preprint":false},{"year":2013,"finding":"HBsAg overexpression in hepatoma cells induces cellular miRNAs that directly repress MICA and MICB expression via their 3'UTRs, reducing surface MICA/B and decreasing NK cell-mediated cytolysis of HCC cells.","method":"miRNA profiling, 3'UTR reporter assays, miRNA inhibitor experiments, flow cytometry, NK cytotoxicity assays","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 — multiple miRNAs validated with 3'UTR reporters and functional NK killing assays, single lab","pmids":["23917076"],"is_preprint":false},{"year":2014,"finding":"Six RNA-binding proteins (RBPs) bind and regulate MICB expression; at least two RBPs function during genotoxic stress; RBP binding was identified through unbiased RNA pull-down combined with mass spectrometry, establishing post-transcriptional regulation of MICB by RBPs.","method":"RNA pull-down assay, mass spectrometry, functional validation of RBP knockdown on MICB expression, genotoxic stress conditions","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 — unbiased proteomics approach with functional follow-up, identification of multiple regulators with mechanistic validation","pmids":["24924487"],"is_preprint":false},{"year":2014,"finding":"Valproic acid (HDAC inhibitor) upregulates MICA and MICB expression on pancreatic cancer cells via the PI3K/Akt signaling pathway; this effect is blocked by PI3K inhibitor LY294002 or PI3K siRNA, and enhances NK cell-mediated cytotoxicity both in vitro and in vivo.","method":"Flow cytometry, qRT-PCR, PI3K inhibitor/siRNA epistasis, xenograft mouse model NK cytotoxicity assays","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 — genetic and pharmacological epistasis placing MICB regulation downstream of PI3K/Akt, confirmed in vivo","pmids":["24885711"],"is_preprint":false},{"year":2016,"finding":"The RNA-binding protein IMP3 indirectly targets MICB expression through a mechanism functionally distinct from its direct interaction with ULBP2 mRNA (which causes transcript destabilization); IMP3-mediated regulation of MICB leads to impaired NK cell recognition of transformed cells.","method":"RIP assay, mRNA stability assays, IMP3 knockdown/overexpression, flow cytometry, NK cell cytotoxicity assays","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 — multiple approaches demonstrating indirect post-transcriptional regulation mechanism, with functional NK cell readout","pmids":["26982091"],"is_preprint":false},{"year":2017,"finding":"Vigilin, an RNA-binding protein, binds to the 5'UTR of MICB mRNA and negatively regulates MICB expression; vigilin downregulation in target cells increases MICB surface expression and significantly enhances NK cell activation against those cells.","method":"RNA pull-down assay, mass spectrometry, RNAi knockdown of vigilin, flow cytometry for MICB, NK activation assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — RNA pull-down identifies binding, functional consequence measured by NK activation, 5'UTR mechanism demonstrated","pmids":["28356383"],"is_preprint":false},{"year":2017,"finding":"ADAM17 (activated by ADAM17) mediates shedding of MICB, MICA, and ULBP2 from AML cell surfaces; hypomethylating agents (AZA, DAC) increase TIMP3 expression by demethylating the TIMP3 gene, and TIMP3 (an ADAM17 inhibitor) reduces soluble MICB shedding, thereby enhancing NKG2D-mediated NK cell recognition.","method":"ADAM17 inhibition, TIMP3 siRNA knockdown, bisulfite sequencing, ELISA for soluble MICB, flow cytometry for NKG2D receptor, NK cytotoxicity assays","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 2 — identifies specific metalloprotease (ADAM17) and its endogenous inhibitor (TIMP3) as mechanism, validated with multiple methods including genetic and pharmacological approaches","pmids":["28404876"],"is_preprint":false},{"year":2017,"finding":"STAT3 inhibition by STA21 increases cell surface MICB expression and soluble MICB secretion from gastric adenocarcinoma cells; recombinant soluble MICB decreases NKG2D receptor levels on NK and CD8+ T cells, impairing their cytolytic activity.","method":"STA21 pharmacological inhibition, flow cytometry, ELISA for soluble MICB, NKG2D receptor expression, NK cytotoxicity assays","journal":"Immunobiology","confidence":"Medium","confidence_rationale":"Tier 2 — STAT3 inhibition with functional readouts, but shedding mechanism not fully characterized mechanistically","pmids":["28578917"],"is_preprint":false},{"year":2018,"finding":"Antibodies targeting the MICB/MICA alpha3 domain prevent proteolytic shedding of MICA and MICB from human cancer cells, maintaining surface expression; this inhibits tumor growth in immunocompetent mouse models primarily through NK cell activation via NKG2D and CD16 Fc receptors.","method":"Antibody engineering, cell surface MICA/B quantification, multiple syngeneic mouse tumor models, NK cell depletion experiments","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 — multiple mouse models with mechanistic dissection of NK cell pathway and receptor involvement, high citation count","pmids":["29599246"],"is_preprint":false},{"year":2018,"finding":"miR-34a has a dual role in MICB regulation: it upregulates ATR kinase (promoting MICB expression) and downregulates E2F1 transcription factor (reducing MICB expression); the net effect on MICB depends on endogenous E2F1 levels, with miR-34a promoting MICB expression in cells with low E2F1.","method":"miR-34a overexpression/inhibition, ATR and E2F1 protein expression analysis, MICB flow cytometry, NK cell cytotoxicity assays","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 — identifies dual regulatory mechanism through two intermediaries, with functional NK cell readout","pmids":["30256916"],"is_preprint":false},{"year":2018,"finding":"MG132 (proteasome inhibitor) selectively upregulates MICB transcription in A549 lung cancer cells via the DNA damage response, specifically through activation of ATM kinase and Chk2 phosphorylation; MG132 increases MICB promoter activity (~1.77-fold) and this is blocked by ATM kinase inhibitor KU-55933.","method":"Luciferase promoter reporter assay, ATM inhibitor epistasis, Chk2 phosphorylation western blot, flow cytometry, NK cytotoxicity assays","journal":"Molecular medicine reports","confidence":"Medium","confidence_rationale":"Tier 2 — promoter reporter assays with inhibitor epistasis establishing DNA damage pathway placement","pmids":["30483783"],"is_preprint":false},{"year":2019,"finding":"LXR (Liver X Receptor) activation regulates MICA and MICB expression through distinct mechanisms: MICA is regulated at the transcriptional level (enhanced mica promoter activity), whereas MICB is regulated by inhibiting its lysosomal degradation; both effects increase surface MICA/B and render multiple myeloma cells more susceptible to NK cell killing.","method":"Promoter reporter assays for MICA, lysosomal pathway inhibitors for MICB, flow cytometry, NK degranulation and killing assays","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — distinct mechanisms for MICA vs MICB demonstrated with multiple assays, single lab","pmids":["31125275"],"is_preprint":false},{"year":2020,"finding":"HDAC inhibitor panobinostat and anti-MICA/B antibody (blocking shedding) synergistically enhance MICB surface expression on tumor cells: panobinostat enhances MICB gene expression, while the antibody stabilizes synthesized protein on the cell surface; the combination reduces pulmonary metastases in humanized NK cell mouse models.","method":"Drug combination assays, flow cytometry, MICB mRNA/protein quantification, humanized NOD/SCID gamma mouse model with human NK cells","journal":"Cancer immunology research","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistically dissects two complementary pathways (transcription vs. shedding) with in vivo validation","pmids":["32209637"],"is_preprint":false},{"year":2013,"finding":"Allelic MICB polymorphisms differentially affect binding to HCMV UL16 protein; MICB*008 (containing methionine at position 98 and asparagine at position 113 in the alpha2 domain) shows decreased binding to UL16 compared to MICB*003, *004, and *00502 (containing isoleucine at 98 and aspartic acid at 113), suggesting MICB*008 may be a protective allele for HCMV immune surveillance.","method":"Flow cytometry binding assay using soluble Fc-fusion UL16 proteins and stable cell lines expressing specific MICB alleles","journal":"Journal of microbiology (Seoul, Korea)","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding measurements with allelic cell lines, identifies specific amino acid positions responsible for differential UL16 binding","pmids":["23625227"],"is_preprint":false},{"year":2003,"finding":"Transgenic mice ubiquitously expressing human MICB show transient neonatal skin hyperkeratosis with epidermal hyperkeratosis, thickened granular layer, and mild inflammatory cell infiltration in the dermis, as well as ~50% leukocytosis, demonstrating an in vivo role for MICB in skin inflammation.","method":"Transgenic mouse generation with ubiquitous MICB promoter, histopathological analysis of skin, blood cell counting","journal":"Tissue antigens","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo transgenic model with histopathological phenotypic readout, two independent transgenic lines confirm phenotype","pmids":["12753668"],"is_preprint":false},{"year":2024,"finding":"A common missense MICB variant (MICBD136N) results in reduced surface MICB expression and reduced NKG2D ligation; cells expressing MICBD136N are less susceptible to NK cell killing, and coculture with NK cells shows less NKG2D activation; in clinical cohorts, MICB variant homozygosity is associated with reduced severity of acute lung injury.","method":"Missense variant protein expression in cultured cells, flow cytometry for surface MICB, NK cell coculture cytotoxicity, BAL NK cell characterization in human subjects, clinical cohort analysis","journal":"American journal of respiratory and critical care medicine","confidence":"High","confidence_rationale":"Tier 2 — functional validation of specific variant in vitro (surface expression, NKG2D ligation, NK killing) confirmed across two independent clinical cohorts","pmids":["37878820"],"is_preprint":false},{"year":2020,"finding":"MICB amino acid position 98 (MICB98) is a key polymorphic residue involved in UL16 binding; mismatches at MICB98 in unrelated-donor hematopoietic cell transplantation are associated with increased acute and chronic GVHD and higher CMV infection/reactivation, establishing MICB98 as a functionally critical position linking UL16 interaction to clinical immune outcomes.","method":"Retrospective clinical study of 943 HCT pairs, MICB98 genotyping, hazard ratio analysis for GVHD and CMV outcomes","journal":"Bone marrow transplantation","confidence":"Medium","confidence_rationale":"Tier 2-3 — large clinical cohort with specific amino acid position identified, but functional mechanism derived from prior structural knowledge rather than direct experiment in this paper","pmids":["32286503"],"is_preprint":false},{"year":2024,"finding":"Linc-ROR promotes ubiquitination and degradation of RXRA (retinoid X receptor alpha) via E3 ligase UBE4B, reducing RXRA availability; since RXRA is a transcription factor for MICB, its degradation leads to reduced MICB surface expression and impaired NK cell-mediated cytotoxicity against gastric cancer cells.","method":"Co-transfection, ubiquitination assays, Linc-ROR overexpression, RXRA protein quantification, flow cytometry for surface MICB, NK-92 cell coculture cytotoxicity assays","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — establishes Linc-ROR → UBE4B → RXRA ubiquitination → MICB reduction pathway with multiple assays","pmids":["38205878"],"is_preprint":false},{"year":2017,"finding":"Novel miRNAs binding to both the 3'UTR and 5'UTR of MICB mRNA reduce MICB expression; mutation of miRNA binding sites in either UTR restores luciferase activity in reporter assays; overexpression of candidate miRNAs reduces and inhibition increases MICB protein surface expression.","method":"Luciferase reporter assays with MICB 3'UTR and 5'UTR constructs, miRNA mimic/inhibitor experiments, flow cytometry","journal":"Genes","confidence":"Medium","confidence_rationale":"Tier 1-2 — 5'UTR and 3'UTR reporter assays with mutagenesis confirming binding sites and protein-level effects, single lab","pmids":["28850101"],"is_preprint":false}],"current_model":"MICB is a stress-induced MHC class I-related surface glycoprotein that acts as a ligand for the NKG2D activating receptor on NK cells, gamma-delta T cells, and CD8+ T cells; its expression is regulated transcriptionally (via NF-Y, Sp1, STAT3, RXRA, and chromatin remodeling) and post-transcriptionally (via cellular and viral miRNAs targeting both 3'UTR and 5'UTR, and RNA-binding proteins including vigilin and IMP3), and is induced by DNA damage through ATM/ATR kinase signaling; surface MICB is shed by metalloproteases (including ADAM15 and ADAM17), with TIMP3 serving as an endogenous inhibitor of shedding; the UL16 protein of HCMV retains MICB intracellularly by binding to its platform domain alpha-helical surface at a site dependent on glutamine-169, and this interaction is allele-dependent (MICB*008/MICBD136N showing reduced binding); at the immunological synapse, MICB drives NKG2D clustering and undergoes bidirectional receptor-ligand transfer that attenuates subsequent NK cell cytotoxicity."},"narrative":{"teleology":[{"year":1999,"claim":"Establishing that MICB functions as a stress-induced antigen recognized by γδ T cells resolved the question of how innate-like lymphocytes detect transformed cells independently of classical peptide–MHC presentation.","evidence":"Cytotoxicity assays with Vδ1 γδ T cell lines against autologous and heterologous tumors expressing MICA/B","pmids":["10359807"],"confidence":"High","gaps":["NKG2D had not yet been identified as the receptor","mechanism of stress-induced MICB upregulation unknown"]},{"year":2001,"claim":"Demonstrating that NKG2D homodimers directly bind monomeric MICA/MICB in solution defined the receptor–ligand pair and revealed that allelic polymorphism at position 129 in the α2 domain governs binding affinity.","evidence":"Solution binding assays with soluble NKG2D and MICA, cell surface binding with MICB, allelic mutagenesis","pmids":["11491531"],"confidence":"High","gaps":["Structural basis of NKG2D–MICB interaction not yet resolved","downstream signaling consequences of affinity differences not explored"]},{"year":2003,"claim":"Transgenic expression of human MICB in mice producing skin hyperkeratosis and leukocytosis provided the first in vivo evidence that MICB drives inflammatory tissue responses.","evidence":"Transgenic mice with ubiquitous MICB expression, histopathology and blood cell counts in two independent lines","pmids":["12753668"],"confidence":"Medium","gaps":["Whether phenotype is NKG2D-dependent was not tested","relevance to endogenous stress-induced expression levels uncertain"]},{"year":2006,"claim":"Two studies established that surface MICB undergoes metalloprotease-mediated shedding to produce a soluble form and that MICB engagement at the NK immunological synapse drives NKG2D clustering, bidirectional receptor–ligand transfer, and subsequent attenuation of NK cytotoxicity.","evidence":"Metalloprotease inhibitor experiments with ELISA/flow cytometry for shedding; live-cell imaging and cytotoxicity assays for synapse dynamics","pmids":["16698441","16849432"],"confidence":"High","gaps":["Identity of the specific sheddase(s) not yet determined","relative contribution of shedding vs. trogocytosis to immune evasion unresolved"]},{"year":2007,"claim":"Characterization of the MICB promoter identified NF-Y (CCAAT box) and Sp1 (GC box) as essential transcription factors and revealed that a natural 2-bp deletion polymorphism causes an 18-fold reduction in promoter activity, while HDAC inhibition upregulates MICB via increased histone H3 acetylation at the promoter.","evidence":"Luciferase reporter/EMSA for promoter elements; ChIP for histone acetylation and HDAC1 occupancy at MICB promoter in leukemic cells","pmids":["17557375","17625602"],"confidence":"High","gaps":["In vivo relevance of the promoter polymorphism not established","full set of transcription factors regulating MICB promoter not mapped"]},{"year":2008,"claim":"Placing MICB induction downstream of ATM/ATR–Chk1 DNA damage signaling—demonstrated via Dicer knockdown and 5-aza-dC treatment with kinase inhibitor epistasis—established the DNA damage response as a central pathway for MICB upregulation.","evidence":"Pharmacological and genetic inhibition of ATM/ATR/Chk1, bisulfite sequencing for DNA methylation, flow cytometry and RT-PCR","pmids":["18644891","18395517"],"confidence":"High","gaps":["Direct transcription factor linking ATM/ATR to MICB promoter activation not identified","contribution of DNA demethylation vs. damage signaling not fully separated"]},{"year":2009,"claim":"Discovery that miRNAs from three divergent herpesviruses (HCMV, KSHV, EBV) convergently target the MICB 3′UTR to suppress expression revealed a conserved viral immune evasion strategy operating at the post-transcriptional level.","evidence":"3′UTR reporter assays with mutagenesis, miRNA mimics/inhibitors, authentic viral infection, NK cytotoxicity assays","pmids":["19380116"],"confidence":"High","gaps":["Full repertoire of cellular miRNAs targeting MICB not known","quantitative contribution of miRNA-mediated suppression relative to other evasion mechanisms unclear"]},{"year":2010,"claim":"The 1.8 Å crystal structure of HCMV UL16 bound to MICB revealed that UL16 mimics NKG2D binding geometry on the MICB platform domain and that glutamine-169 is the critical determinant for UL16 engagement, explaining why MICA (arginine-169) escapes UL16 retention.","evidence":"X-ray crystallography, surface plasmon resonance, site-directed mutagenesis","pmids":["20090832"],"confidence":"High","gaps":["How UL16 retains MICB intracellularly (trafficking mechanism) not resolved","structure of UL16–MICB in membrane context unknown"]},{"year":2013,"claim":"Identification of ADAM15 as a MICB sheddase and of allelic variation at MICB positions 98 and 113 as determinants of UL16 binding specificity provided molecular explanations for differential immune evasion across MICB alleles.","evidence":"siRNA knockdown of ADAM15 with surface/soluble MICB quantification; Fc-fusion UL16 binding to MICB allelic cell lines","pmids":["23314034","23625227"],"confidence":"Medium","gaps":["Relative contributions of ADAM15 vs. other ADAMs to shedding in different tissues not determined","MICB allele-specific UL16 binding not validated structurally"]},{"year":2014,"claim":"Unbiased RNA pull-down/mass spectrometry identified six RNA-binding proteins regulating MICB, at least two functioning during genotoxic stress, establishing post-transcriptional control as a major regulatory axis beyond miRNAs.","evidence":"RNA pull-down with MICB UTRs, mass spectrometry, RBP knockdown with MICB expression readout under genotoxic stress","pmids":["24924487"],"confidence":"High","gaps":["Precise binding sites and mechanism for most identified RBPs not characterized","whether RBPs and miRNAs act cooperatively or redundantly unknown"]},{"year":2017,"claim":"Three discoveries refined the post-transcriptional and post-translational regulation of MICB: vigilin was identified as a 5′UTR-binding repressor, ADAM17 was shown to be the principal sheddase inhibitable by TIMP3, and novel miRNAs targeting both the 3′UTR and 5′UTR were validated.","evidence":"RNA pull-down/MS for vigilin; ADAM17 inhibition and TIMP3 siRNA with shedding assays; luciferase reporters with UTR mutagenesis","pmids":["28356383","28404876","28850101"],"confidence":"Medium","gaps":["Structural basis for vigilin–5′UTR interaction unknown","relative importance of ADAM15 vs. ADAM17 across cell types not compared","functional redundancy among UTR-targeting miRNAs not assessed"]},{"year":2018,"claim":"Antibodies targeting the MICA/MICB α3 domain that block proteolytic shedding demonstrated therapeutic proof-of-concept by maintaining surface NKG2D ligand density and inhibiting tumor growth through NK cell activation via NKG2D and CD16.","evidence":"Antibody engineering, surface MICA/B quantification, multiple syngeneic mouse tumor models with NK depletion","pmids":["29599246"],"confidence":"High","gaps":["Whether anti-shedding antibodies affect MICB and MICA equally not fully resolved","contribution of adaptive immune components beyond NK cells not characterized"]},{"year":2024,"claim":"A common MICB missense variant (D136N) was shown to reduce surface expression and NKG2D-mediated NK killing, with clinical validation linking homozygosity to reduced acute lung injury severity, directly connecting MICB genetic variation to human disease outcomes.","evidence":"Variant protein expression in cells, flow cytometry, NK coculture, two independent clinical cohorts","pmids":["37878820"],"confidence":"High","gaps":["Structural basis for D136N effect on surface expression unknown","whether D136N also affects UL16 or other viral immunoevasin binding not tested"]},{"year":2024,"claim":"The lncRNA Linc-ROR was found to suppress MICB by promoting UBE4B-mediated ubiquitination and degradation of the transcription factor RXRA, adding a new upstream regulatory layer to MICB transcriptional control.","evidence":"Co-transfection, ubiquitination assays, RXRA protein quantification, flow cytometry for MICB, NK-92 coculture","pmids":["38205878"],"confidence":"Medium","gaps":["Whether RXRA binds the MICB promoter directly not demonstrated by ChIP","generalizability beyond gastric cancer cells not established"]},{"year":null,"claim":"The precise transcription factor cascade linking ATM/ATR activation to MICB promoter induction remains unidentified, and a unified model integrating transcriptional, post-transcriptional (miRNA/RBP), and post-translational (shedding/lysosomal degradation) control of MICB surface density has not been established.","evidence":"","pmids":[],"confidence":"Low","gaps":["No transcription factor directly connecting ATM/ATR kinase activity to MICB promoter has been identified","Quantitative contributions of shedding, trogocytosis, and miRNA suppression to MICB surface levels in physiological contexts are unknown","Full structural basis of allelic MICB variation on NKG2D vs. viral immunoevasin binding not comprehensively mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,3,27]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,3,12,18,20,27]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,3,8,20,27]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[6,7,22]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[4,5,29]}],"complexes":[],"partners":["KLRK1","ADAM17","ADAM15","HDAC1"],"other_free_text":[]},"mechanistic_narrative":"MICB is a stress-induced MHC class I-related surface glycoprotein that serves as a ligand for the NKG2D activating receptor, triggering cytotoxic responses by NK cells, γδ T cells, and CD8+ T cells against transformed and infected cells [PMID:10359807, PMID:11491531]. MICB expression is controlled at multiple levels: transcriptionally by NF-Y, Sp1, STAT3, and RXRA through a polymorphic promoter whose activity is modulated by chromatin remodeling via histone acetylation and DNA methylation [PMID:17557375, PMID:17625602, PMID:18395517, PMID:29]; post-transcriptionally by cellular and viral miRNAs targeting both the 3′UTR and 5′UTR, and by RNA-binding proteins including vigilin and IMP3 [PMID:19380116, PMID:28850101, PMID:28356383, PMID:26982091]; and at the protein level by metalloprotease-mediated ectodomain shedding (ADAM15, ADAM17) counteracted by the endogenous inhibitor TIMP3 [PMID:16698441, PMID:23314034, PMID:28404876]. MICB induction is linked to the DNA damage response through ATM/ATR–Chk1/Chk2 signaling [PMID:18644891, PMID:30483783], and surface MICB is targeted for immune evasion by herpesvirus proteins such as HCMV UL16, which binds the MICB platform domain at a glutamine-169-dependent site to retain it intracellularly, with allelic variation at positions 98 and 113 modulating this interaction [PMID:20090832, PMID:23625227]. A common MICB missense variant (D136N) reduces surface expression and NKG2D-mediated NK killing and is associated with reduced acute lung injury severity [PMID:37878820]."},"prefetch_data":{"uniprot":{"accession":"Q29980","full_name":"MHC class I polypeptide-related sequence B","aliases":[],"length_aa":383,"mass_kda":42.6,"function":"Widely expressed membrane-bound protein which acts as a ligand to stimulate an activating receptor KLRK1/NKG2D, expressed on the surface of essentially all human natural killer (NK), gammadelta T and CD8+ alphabeta T-cells (PubMed:11491531, PubMed:11777960). Up-regulated in stressed conditions, such as viral and bacterial infections or DNA damage response, serves as signal of cellular stress, and engagement of KLRK1/NKG2D by MICA triggers NK-cells resulting in a range of immune effector functions, such as cytotoxicity and cytokine production","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q29980/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MICB","classification":"Not Classified","n_dependent_lines":32,"n_total_lines":1208,"dependency_fraction":0.026490066225165563},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MICB","total_profiled":1310},"omim":[{"mim_id":"614371","title":"DENGUE VIRUS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/614371"},{"mim_id":"611817","title":"KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY K, MEMBER 1; KLRK1","url":"https://www.omim.org/entry/611817"},{"mim_id":"605699","title":"UL16-BINDING PROTEIN 3; ULBP3","url":"https://www.omim.org/entry/605699"},{"mim_id":"605698","title":"UL16-BINDING PROTEIN 2; ULBP2","url":"https://www.omim.org/entry/605698"},{"mim_id":"605697","title":"UL16-BINDING PROTEIN 1; ULBP1","url":"https://www.omim.org/entry/605697"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":9.4}],"url":"https://www.proteinatlas.org/search/MICB"},"hgnc":{"alias_symbol":["PERB11.2"],"prev_symbol":[]},"alphafold":{"accession":"Q29980","domains":[{"cath_id":"3.30.500.10","chopping":"25-200","consensus_level":"high","plddt":92.2753,"start":25,"end":200},{"cath_id":"2.60.40.10","chopping":"206-293","consensus_level":"high","plddt":93.3194,"start":206,"end":293}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q29980","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q29980-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q29980-F1-predicted_aligned_error_v6.png","plddt_mean":78.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MICB","jax_strain_url":"https://www.jax.org/strain/search?query=MICB"},"sequence":{"accession":"Q29980","fasta_url":"https://rest.uniprot.org/uniprotkb/Q29980.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q29980/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q29980"}},"corpus_meta":[{"pmid":"10359807","id":"PMC_10359807","title":"Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10359807","citation_count":831,"is_preprint":false},{"pmid":"19380116","id":"PMC_19380116","title":"Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells.","date":"2009","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/19380116","citation_count":383,"is_preprint":false},{"pmid":"29599246","id":"PMC_29599246","title":"Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.","date":"2018","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/29599246","citation_count":378,"is_preprint":false},{"pmid":"11491531","id":"PMC_11491531","title":"Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family.","date":"2001","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11491531","citation_count":377,"is_preprint":false},{"pmid":"12569559","id":"PMC_12569559","title":"Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid.","date":"2003","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12569559","citation_count":195,"is_preprint":false},{"pmid":"22001756","id":"PMC_22001756","title":"Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1.","date":"2011","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22001756","citation_count":169,"is_preprint":false},{"pmid":"11429322","id":"PMC_11429322","title":"MICA and MICB genes: can the enigma of their polymorphism be resolved?","date":"2001","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11429322","citation_count":160,"is_preprint":false},{"pmid":"16698441","id":"PMC_16698441","title":"Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients.","date":"2006","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16698441","citation_count":121,"is_preprint":false},{"pmid":"10523017","id":"PMC_10523017","title":"Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison's disease.","date":"1999","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10523017","citation_count":120,"is_preprint":false},{"pmid":"22915757","id":"PMC_22915757","title":"MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22915757","citation_count":108,"is_preprint":false},{"pmid":"32209637","id":"PMC_32209637","title":"Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.","date":"2020","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/32209637","citation_count":107,"is_preprint":false},{"pmid":"16636811","id":"PMC_16636811","title":"Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA.","date":"2006","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/16636811","citation_count":104,"is_preprint":false},{"pmid":"17625602","id":"PMC_17625602","title":"Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells.","date":"2007","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/17625602","citation_count":99,"is_preprint":false},{"pmid":"28334733","id":"PMC_28334733","title":"MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue.","date":"2017","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28334733","citation_count":92,"is_preprint":false},{"pmid":"17565371","id":"PMC_17565371","title":"In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer.","date":"2007","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/17565371","citation_count":83,"is_preprint":false},{"pmid":"9321430","id":"PMC_9321430","title":"Allelic variants of the human MHC class I chain-related B gene (MICB).","date":"1997","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/9321430","citation_count":74,"is_preprint":false},{"pmid":"16849432","id":"PMC_16849432","title":"Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16849432","citation_count":74,"is_preprint":false},{"pmid":"18644891","id":"PMC_18644891","title":"Decreased Dicer expression elicits DNA damage and up-regulation of MICA and MICB.","date":"2008","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18644891","citation_count":68,"is_preprint":false},{"pmid":"11443095","id":"PMC_11443095","title":"Competence repression under oxygen limitation through the two-component MicAB signal-transducing system in Streptococcus pneumoniae and involvement of the PAS domain of MicB.","date":"2001","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/11443095","citation_count":62,"is_preprint":false},{"pmid":"12022360","id":"PMC_12022360","title":"MICA rather than MICB, TNFA, or HLA-DRB1 is associated with susceptibility to psoriatic arthritis.","date":"2002","source":"The Journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/12022360","citation_count":58,"is_preprint":false},{"pmid":"17557375","id":"PMC_17557375","title":"Transcriptional regulation of MICA and MICB: a novel polymorphism in MICB promoter alters transcriptional regulation by Sp1.","date":"2007","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17557375","citation_count":57,"is_preprint":false},{"pmid":"24885711","id":"PMC_24885711","title":"Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24885711","citation_count":55,"is_preprint":false},{"pmid":"18395517","id":"PMC_18395517","title":"Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18395517","citation_count":53,"is_preprint":false},{"pmid":"16641608","id":"PMC_16641608","title":"Expression of MHC class I-related Chain B (MICB) molecules on renal transplant biopsies.","date":"2006","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/16641608","citation_count":45,"is_preprint":false},{"pmid":"11782275","id":"PMC_11782275","title":"MICA, MICB and C1_4_1 polymorphism in Crohn's disease and ulcerative colitis.","date":"2001","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/11782275","citation_count":44,"is_preprint":false},{"pmid":"26982091","id":"PMC_26982091","title":"The RNA binding protein IMP3 facilitates tumor immune escape by downregulating the stress-induced ligands ULPB2 and MICB.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/26982091","citation_count":44,"is_preprint":false},{"pmid":"20090832","id":"PMC_20090832","title":"Structure of the HCMV UL16-MICB complex elucidates select binding of a viral immunoevasin to diverse NKG2D ligands.","date":"2010","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/20090832","citation_count":43,"is_preprint":false},{"pmid":"11169252","id":"PMC_11169252","title":"Wide distribution of the MICA-MICB null haplotype in East Asians.","date":"2001","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/11169252","citation_count":41,"is_preprint":false},{"pmid":"22102813","id":"PMC_22102813","title":"The human herpesvirus-7 (HHV-7) U21 immunoevasin subverts NK-mediated cytoxicity through modulation of MICA and MICB.","date":"2011","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/22102813","citation_count":41,"is_preprint":false},{"pmid":"23917076","id":"PMC_23917076","title":"Hepatitis B surface antigen inhibits MICA and MICB expression via induction of cellular miRNAs in hepatocellular carcinoma cells.","date":"2013","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/23917076","citation_count":39,"is_preprint":false},{"pmid":"28404876","id":"PMC_28404876","title":"Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28404876","citation_count":39,"is_preprint":false},{"pmid":"17003176","id":"PMC_17003176","title":"MHC class I chain-related gene B (MICB) is associated with rheumatoid arthritis susceptibility.","date":"2006","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/17003176","citation_count":37,"is_preprint":false},{"pmid":"11034563","id":"PMC_11034563","title":"On the MICA deleted-MICB null, HLA-B*4801 haplotype.","date":"2000","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/11034563","citation_count":37,"is_preprint":false},{"pmid":"12175734","id":"PMC_12175734","title":"High resolution molecular phototyping of MICA and MICB alleles using sequence specific primers.","date":"2002","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12175734","citation_count":35,"is_preprint":false},{"pmid":"21762746","id":"PMC_21762746","title":"Association of MICA and MICB alleles with symptomatic dengue infection.","date":"2011","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21762746","citation_count":34,"is_preprint":false},{"pmid":"17561376","id":"PMC_17561376","title":"Polymorphisms in MICB are associated with human herpes virus seropositivity and schizophrenia risk.","date":"2007","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/17561376","citation_count":34,"is_preprint":false},{"pmid":"9712354","id":"PMC_9712354","title":"Microsatellite polymorphism within the MICB gene among Japanese patients with Behçet's disease.","date":"1998","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9712354","citation_count":34,"is_preprint":false},{"pmid":"16923796","id":"PMC_16923796","title":"Variation in MICA and MICB genes and enhanced susceptibility to paucibacillary leprosy in South India.","date":"2006","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16923796","citation_count":33,"is_preprint":false},{"pmid":"9694358","id":"PMC_9694358","title":"Sequencing-based typing reveals six novel MHC class I chain-related gene B (MICB) alleles.","date":"1998","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/9694358","citation_count":32,"is_preprint":false},{"pmid":"21036725","id":"PMC_21036725","title":"Soluble MICB serum levels correlate with disease stage and survival rate in patients with oral squamous cell carcinoma.","date":"2010","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21036725","citation_count":28,"is_preprint":false},{"pmid":"21477352","id":"PMC_21477352","title":"Expression of MICA, MICB and NKG2D in human leukemic myelomonocytic and cervical cancer cells.","date":"2011","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/21477352","citation_count":28,"is_preprint":false},{"pmid":"12671735","id":"PMC_12671735","title":"MICB typing by PCR amplification with sequence specific primers.","date":"2003","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/12671735","citation_count":28,"is_preprint":false},{"pmid":"24924487","id":"PMC_24924487","title":"RNA-binding proteins regulate the expression of the immune activating ligand MICB.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24924487","citation_count":27,"is_preprint":false},{"pmid":"24884822","id":"PMC_24884822","title":"A replication study confirms the association of GWAS-identified SNPs at MICB and PLCE1 in Thai patients with dengue shock syndrome.","date":"2014","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24884822","citation_count":27,"is_preprint":false},{"pmid":"16101831","id":"PMC_16101831","title":"The haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy.","date":"2005","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/16101831","citation_count":26,"is_preprint":false},{"pmid":"21664939","id":"PMC_21664939","title":"Characterization of the major histocompatibility complex class I chain-related gene B (MICB) polymorphism in a northern Chinese Han population: the identification of a new MICB allele, MICB*023.","date":"2011","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21664939","citation_count":26,"is_preprint":false},{"pmid":"15089901","id":"PMC_15089901","title":"Association of MHC class I related gene B (MICB) to celiac disease.","date":"2004","source":"The American journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/15089901","citation_count":25,"is_preprint":false},{"pmid":"31125275","id":"PMC_31125275","title":"Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31125275","citation_count":25,"is_preprint":false},{"pmid":"20566410","id":"PMC_20566410","title":"HIF-1alpha accumulation upregulates MICA and MICB expression on human cardiomyocytes and enhances NK cell cytotoxicity during hypoxia-reoxygenation.","date":"2010","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20566410","citation_count":25,"is_preprint":false},{"pmid":"11862397","id":"PMC_11862397","title":"Alu polymorphism within the MICB gene and association with HLA-B alleles.","date":"2002","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11862397","citation_count":24,"is_preprint":false},{"pmid":"18588574","id":"PMC_18588574","title":"Genetic influence of the nonclassical major histocompatibility complex class I molecule MICB in multiple sclerosis susceptibility.","date":"2008","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/18588574","citation_count":22,"is_preprint":false},{"pmid":"28850101","id":"PMC_28850101","title":"5'-UTR and 3'-UTR Regulation of MICB Expression in Human Cancer Cells by Novel microRNAs.","date":"2017","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/28850101","citation_count":21,"is_preprint":false},{"pmid":"27028549","id":"PMC_27028549","title":"MICA, MICB Polymorphisms and Linkage Disequilibrium with HLA-B in a Chinese Mongolian Population.","date":"2016","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27028549","citation_count":21,"is_preprint":false},{"pmid":"24962621","id":"PMC_24962621","title":"Diversity and characterization of polymorphic 5' promoter haplotypes of MICA and MICB genes.","date":"2014","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/24962621","citation_count":21,"is_preprint":false},{"pmid":"18505429","id":"PMC_18505429","title":"Associations of MICB with cervical cancer in north-eastern Thais: identification of major histocompatibility complex class I chain-related gene B motifs influencing natural killer cell activation.","date":"2008","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18505429","citation_count":21,"is_preprint":false},{"pmid":"21554252","id":"PMC_21554252","title":"MICB polymorphisms and haplotypes with MICA and HLA alleles in Koreans.","date":"2011","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/21554252","citation_count":20,"is_preprint":false},{"pmid":"11881819","id":"PMC_11881819","title":"MICA and MICB microsatellite alleles in HLA extended haplotypes.","date":"2001","source":"European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11881819","citation_count":20,"is_preprint":false},{"pmid":"12242594","id":"PMC_12242594","title":"High frequency of MIC null haplotype (HLA-B48-MICA-del-MICB*0107 N) in the Angaite Amerindian community in Paraguay.","date":"2002","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/12242594","citation_count":20,"is_preprint":false},{"pmid":"10746790","id":"PMC_10746790","title":"Three novel MICB alleles.","date":"2000","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/10746790","citation_count":19,"is_preprint":false},{"pmid":"17181741","id":"PMC_17181741","title":"MICA and MICB overexpression in oral squamous cell carcinoma.","date":"2007","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17181741","citation_count":18,"is_preprint":false},{"pmid":"11929594","id":"PMC_11929594","title":"The nucleotide diversity of MICA and MICB suggests the effect of overdominant selection.","date":"2001","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/11929594","citation_count":17,"is_preprint":false},{"pmid":"22609444","id":"PMC_22609444","title":"MICB polymorphism in a southern Chinese Han population: the identification of two new MICB alleles, MICB*005:06 and MICB*026.","date":"2012","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22609444","citation_count":17,"is_preprint":false},{"pmid":"28578917","id":"PMC_28578917","title":"STAT3 inhibition by STA21 increases cell surface expression of MICB and the release of soluble MICB by gastric adenocarcinoma cells.","date":"2017","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28578917","citation_count":17,"is_preprint":false},{"pmid":"11929593","id":"PMC_11929593","title":"Linkage disequilibria between HLA-B, C1_4_1, MICA and MICB.","date":"2001","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/11929593","citation_count":14,"is_preprint":false},{"pmid":"15304009","id":"PMC_15304009","title":"Study on the haplotypes of MICA and MICB microsatellite and HLA-B locus in the Guangzhou Han population.","date":"2004","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/15304009","citation_count":13,"is_preprint":false},{"pmid":"28944101","id":"PMC_28944101","title":"Soluble MICB in Plasma and Urine Explains Population Expansions of NKG2D+CD4 T Cells Inpatients with Juvenile-Onset Systemic Lupus Erythematosus.","date":"2017","source":"Open journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28944101","citation_count":13,"is_preprint":false},{"pmid":"23549730","id":"PMC_23549730","title":"Distribution of MICB diversity in the Zhejiang Han population: PCR sequence-based typing for exons 2-6 and identification of five novel MICB alleles.","date":"2013","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/23549730","citation_count":13,"is_preprint":false},{"pmid":"32286503","id":"PMC_32286503","title":"Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status.","date":"2020","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/32286503","citation_count":12,"is_preprint":false},{"pmid":"10583461","id":"PMC_10583461","title":"Novel intronic variants of MICB (MHC class I chain-related gene B).","date":"1999","source":"European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/10583461","citation_count":12,"is_preprint":false},{"pmid":"12466900","id":"PMC_12466900","title":"Alternatively spliced forms of MICA and MICB lacking exon 3 in a human cell line and evidence of presence of similar RNA in human peripheral blood mononuclear cells.","date":"2002","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/12466900","citation_count":12,"is_preprint":false},{"pmid":"30256916","id":"PMC_30256916","title":"MicroRNA-34a promotes MICB expression in hepatocytes.","date":"2018","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/30256916","citation_count":11,"is_preprint":false},{"pmid":"30483783","id":"PMC_30483783","title":"MG132 selectively upregulates MICB through the DNA damage response pathway in A549 cells.","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30483783","citation_count":11,"is_preprint":false},{"pmid":"23314034","id":"PMC_23314034","title":"ADAM15 is involved in MICB shedding and mediates the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cells.","date":"2013","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/23314034","citation_count":11,"is_preprint":false},{"pmid":"27026046","id":"PMC_27026046","title":"MMP9 Promoter Polymorphism (-1562 C/T) Does not Affect the Serum Levels of Soluble MICB and MICA in Breast Cancer.","date":"2016","source":"Iranian journal of immunology : IJI","url":"https://pubmed.ncbi.nlm.nih.gov/27026046","citation_count":11,"is_preprint":false},{"pmid":"16679067","id":"PMC_16679067","title":"MICB microsatellite polymorphism is associated with ulcerative colitis in Chinese population.","date":"2006","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/16679067","citation_count":11,"is_preprint":false},{"pmid":"37878820","id":"PMC_37878820","title":"MICB Genomic Variant Is Associated with NKG2D-mediated Acute Lung Injury and Death.","date":"2024","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37878820","citation_count":9,"is_preprint":false},{"pmid":"34682758","id":"PMC_34682758","title":"Single-Nucleotide Polymorphisms in MICA and MICB Genes Could Play a Role in the Outcome in AML Patients after HSCT.","date":"2021","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34682758","citation_count":9,"is_preprint":false},{"pmid":"28356383","id":"PMC_28356383","title":"Vigilin Regulates the Expression of the Stress-Induced Ligand MICB by Interacting with Its 5' Untranslated Region.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28356383","citation_count":9,"is_preprint":false},{"pmid":"15304008","id":"PMC_15304008","title":"Eight novel MICB alleles, including a null allele, identified in gastric MALT lymphoma patients.","date":"2004","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/15304008","citation_count":9,"is_preprint":false},{"pmid":"33599111","id":"PMC_33599111","title":"High-throughput genotyping of HLA-G, HLA-F, MICA, and MICB and analysis of frequency distributions in healthy blood donors from Catalonia.","date":"2021","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/33599111","citation_count":9,"is_preprint":false},{"pmid":"33835601","id":"PMC_33835601","title":"Associations of high-resolution-typing-defined MICA and MICB polymorphisms, and the levels of soluble MICA and MICB with Oral Squamous Cell Carcinoma in Bulgarian patients.","date":"2021","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33835601","citation_count":9,"is_preprint":false},{"pmid":"23479551","id":"PMC_23479551","title":"Metastamir-mediated immune evasion: miR-10b downregulates the stress-induced molecule MICB, hence avoid recognition by NKG2D receptor.","date":"2013","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/23479551","citation_count":9,"is_preprint":false},{"pmid":"21388352","id":"PMC_21388352","title":"Impact of MICA-TM, MICB-C1_2_A and C1_4_1 microsatellite polymorphisms on the susceptibility to chronic periodontitis in Germany.","date":"2011","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/21388352","citation_count":8,"is_preprint":false},{"pmid":"23380144","id":"PMC_23380144","title":"Characterization of 3'untranslated region (3'UTR) of the MICB gene.","date":"2013","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23380144","citation_count":7,"is_preprint":false},{"pmid":"31435903","id":"PMC_31435903","title":"Inhibiting exosomal MIC-A and MIC-B shedding of cancer cells to overcome immune escape: new insight of approved drugs.","date":"2019","source":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31435903","citation_count":7,"is_preprint":false},{"pmid":"27038471","id":"PMC_27038471","title":"In silico transcriptional regulation and functional analysis of dengue shock syndrome associated SNPs in PLCE1 and MICB genes.","date":"2016","source":"Functional & integrative genomics","url":"https://pubmed.ncbi.nlm.nih.gov/27038471","citation_count":6,"is_preprint":false},{"pmid":"23625227","id":"PMC_23625227","title":"Allelic MHC class I chain related B (MICB) molecules affect the binding to the human cytomegalovirus (HCMV) unique long 16 (UL16) protein: implications for immune surveillance.","date":"2013","source":"Journal of microbiology (Seoul, Korea)","url":"https://pubmed.ncbi.nlm.nih.gov/23625227","citation_count":6,"is_preprint":false},{"pmid":"36958849","id":"PMC_36958849","title":"Associations between MICA and MICB Genetic Variants, Protein Levels, and Colorectal Cancer: Atherosclerosis Risk in Communities (ARIC).","date":"2023","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36958849","citation_count":6,"is_preprint":false},{"pmid":"32737971","id":"PMC_32737971","title":"Major Histocompatibility Complex Class I Chain-Related A and B (MICA and MICB) Gene, Allele, and Haplotype Associations With Dengue Infections in Ethnic Thais.","date":"2020","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32737971","citation_count":6,"is_preprint":false},{"pmid":"12753668","id":"PMC_12753668","title":"Hyperkeratosis and leukocytosis in transgenic mice carrying MHC class I chain-related gene B (MICB).","date":"2003","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/12753668","citation_count":5,"is_preprint":false},{"pmid":"27433477","id":"PMC_27433477","title":"Polymorphism rs3828903 within MICB Is Associated with Susceptibility to Systemic Lupus Erythematosus in a Northern Han Chinese Population.","date":"2016","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/27433477","citation_count":5,"is_preprint":false},{"pmid":"29665245","id":"PMC_29665245","title":"MICB*002 and MICB*014 protect against rheumatoid arthritis, whereas MICA*009 and MICA*A6 are associated with rheumatoid arthritis in a Hainan Han Chinese population.","date":"2018","source":"International journal of rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/29665245","citation_count":5,"is_preprint":false},{"pmid":"25626490","id":"PMC_25626490","title":"Soluble MICB protein levels and platelet counts during hepatitis B virus infection and response to hepatocellular carcinoma treatment.","date":"2015","source":"BMC infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/25626490","citation_count":5,"is_preprint":false},{"pmid":"35525711","id":"PMC_35525711","title":"HLA class I chain-related MICA and MICB genes polymorphism in healthy individuals from the Bulgarian population.","date":"2022","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35525711","citation_count":4,"is_preprint":false},{"pmid":"30471210","id":"PMC_30471210","title":"Diversity and characterisation of polymorphic 3' untranslated region haplotypes of MICA and MICB genes.","date":"2018","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/30471210","citation_count":4,"is_preprint":false},{"pmid":"15807254","id":"PMC_15807254","title":"[Effect of hypoxia/reoxygenation (H/R) on expression of MICA and MICB in human hepatocytes].","date":"2005","source":"Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition","url":"https://pubmed.ncbi.nlm.nih.gov/15807254","citation_count":4,"is_preprint":false},{"pmid":"30332343","id":"PMC_30332343","title":"Single-Nucleotide Polymorphisms in NOD1, RIPK2, MICB, PLCE1, TNF, and IKBKE Genes Associated with Symptomatic Dengue in Children from Colombia.","date":"2018","source":"Viral immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30332343","citation_count":4,"is_preprint":false},{"pmid":"38205878","id":"PMC_38205878","title":"Linc-ROR inhibits NK cell-killing activity by promoting RXRA ubiquitination and reducing MICB expression in gastric cancer patients.","date":"2024","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38205878","citation_count":4,"is_preprint":false},{"pmid":"30214691","id":"PMC_30214691","title":"Correction: Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/30214691","citation_count":4,"is_preprint":false},{"pmid":"39871443","id":"PMC_39871443","title":"Identification of Novel MICB Alleles in Haematopoietic Stem Cell Donors of Indian Origin.","date":"2025","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/39871443","citation_count":3,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48950,"output_tokens":7450,"usd":0.1293},"stage2":{"model":"claude-opus-4-6","input_tokens":11156,"output_tokens":3624,"usd":0.21957},"total_usd":0.34887,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"MICA and MICB are stress-induced antigens recognized by gamma delta T cells expressing Vdelta1 variable region, acting as tumor-associated antigens that trigger cytotoxic responses without peptide antigen constraints.\",\n      \"method\": \"T cell recognition assays using tumor-derived Vdelta1 gamma delta T cell lines and clones against autologous and heterologous tumor cells expressing MICA/B\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional cytotoxicity assays replicated across multiple tumor types and T cell clones from different tumors, high citation count indicating foundational study\",\n      \"pmids\": [\"10359807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"NKG2D homodimers form stable complexes with monomeric MICA in solution without requiring additional components; NKG2D also binds cell surface MICB; MICA glycosylation enhances but is not essential for complex formation; allelic variants of MICA show large differences in NKG2D binding associated with a single amino acid substitution at position 129 in the alpha2 domain.\",\n      \"method\": \"Solution binding assays (soluble NKG2D and MICA), cell surface binding with soluble NKG2D, allelic mutagenesis analysis\",\n      \"journal\": \"Immunogenetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted binding in solution plus functional validation with allelic variants, high citation count\",\n      \"pmids\": [\"11491531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MICB is shed by metalloproteases from tumor cell surfaces in soluble form; cell-bound MICB causes downregulation of surface NKG2D on NK cells, whereas soluble MICB did not alter NKG2D expression on NK cells in vitro, suggesting shedding impairs tumor immunogenicity primarily by reducing NKG2D-ligand density on malignant cells.\",\n      \"method\": \"Metalloprotease inhibitor experiments, NK cell NKG2D expression assays by flow cytometry, ELISA for soluble MICB in patient sera\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (biochemical shedding assays, flow cytometry, patient sera ELISA)\",\n      \"pmids\": [\"16698441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"NKG2D and MICB undergo bidirectional intercellular transfer at the cytotoxic NK cell immune synapse (cNK-IS); MICB on target cells induces NKG2D clustering at the central supramolecular activation cluster (cSMAC) surrounded by F-actin at the peripheral SMAC; membrane-connective structures at cNK-IS contain F-actin, perforin, and NKG2D; brief NK–MICB+ target cell interactions reduce NKG2D-dependent NK cytotoxicity.\",\n      \"method\": \"Live cell imaging, immunofluorescence microscopy, cytotoxicity assays with MICB-expressing target cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct imaging of protein transfer, functional consequence measured by cytotoxicity assay, multiple orthogonal methods\",\n      \"pmids\": [\"16849432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"HDAC inhibitor trichostatin A (TsA) increases MICA and MICB expression on leukemic cells by increasing histone H3 acetylation and decreasing HDAC1 association at MICA and MICB promoters, leading to enhanced NKG2D-mediated cytotoxicity against leukemic cells.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) assay, flow cytometry, cytotoxicity assays\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP directly demonstrates chromatin remodeling at MICB promoter, linked to functional NK cytotoxicity outcome\",\n      \"pmids\": [\"17625602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The MICB promoter is polymorphic; a 2-bp deletion near the CCAAT box (-70) and GC box (-86) dramatically reduces MICB transcriptional activity (18-fold decrease) by diminishing Sp1 transcriptional activation; the minimal MICB promoter contains NF-Y binding (CCAAT box) and Sp1/Sp3/Sp4 binding (GC box) elements.\",\n      \"method\": \"Luciferase reporter assays, promoter deletion analysis, electrophoretic mobility shift assay (EMSA), functional transcription analysis\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro transcriptional assays with mutagenesis and functional validation of specific transcription factor binding\",\n      \"pmids\": [\"17557375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Knockdown of Dicer in human cells induces DNA damage and upregulates MICA and MICB expression; this upregulation is prevented by pharmacological or genetic inhibition of ATM kinase, ATR kinase, or Chk1, establishing that MICB upregulation following Dicer knockdown is mediated through the DNA damage response pathway.\",\n      \"method\": \"RNAi knockdown of Dicer, pharmacological inhibition (ATM, ATR, Chk1 inhibitors), genetic inhibition, flow cytometry/RT-PCR for MICA/B expression\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological perturbations establishing pathway placement of MICB regulation downstream of DNA damage response\",\n      \"pmids\": [\"18644891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"5-aza-2'-deoxycytidine (5-aza-dC) upregulates MICB expression through promoter DNA demethylation combined with DNA damage; ATM kinase inhibition partially prevents this upregulation, indicating that both DNA demethylation and ATM-mediated DNA damage signaling contribute to MICB induction.\",\n      \"method\": \"Bisulfite sequencing for DNA methylation, pharmacological ATM inhibition, RT-PCR/flow cytometry for MICB expression\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — two orthogonal mechanisms identified (methylation + DNA damage), single lab\",\n      \"pmids\": [\"18395517\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MicroRNAs from diverse herpesviruses (HCMV, KSHV, EBV) directly target MICB mRNA at different but adjacent sites in its 3'UTR to repress MICB expression and enable NK cell evasion; despite lacking sequence homology, these viral miRNAs are functionally conserved in targeting MICB during authentic viral infection.\",\n      \"method\": \"Reporter assays with MICB 3'UTR, miRNA mimic/inhibitor experiments, authentic viral infection, NK cell cytotoxicity assays\",\n      \"journal\": \"Cell host & microbe\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstituted 3'UTR targeting demonstrated with mutagenesis, validated in authentic viral infection, multiple virus species, high citation count\",\n      \"pmids\": [\"19380116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Crystal structure of HCMV UL16 in complex with MICB at 1.8 Å resolution reveals that UL16 uses a three-stranded beta-sheet to engage the alpha-helical surface of the MICB MHC class I-like platform domain, mimicking the NKG2D binding mode; UL16 binds MICB, ULBP1, and ULBP2 with nanomolar affinity (12–66 nM); binding requires glutamine at position 169 of MICB, and an arginine at this position (as in MICA or ULBP3) causes steric clashes preventing UL16 binding.\",\n      \"method\": \"X-ray crystallography (1.8 Å), surface plasmon resonance, mutagenesis\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with SPR affinity measurements and mutagenesis confirming binding determinants\",\n      \"pmids\": [\"20090832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HHV-7 U21 immunoevasin binds to NK-activating ligands MICA and MICB and downregulates their surface expression, resulting in reduced NK-mediated cytotoxicity; this is mechanistically distinct from U21's known downregulation of class I MHC.\",\n      \"method\": \"Flow cytometry for MICB/MICA surface expression in U21-expressing cells, NK cytotoxicity assays\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding and surface downregulation measured with functional NK cytotoxicity readout, single lab\",\n      \"pmids\": [\"22102813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"miR-10b directly binds to the 3'UTR of MICB mRNA and downregulates MICB surface expression; antagonizing miR-10b enhanced NKG2D-mediated NK cell killing of tumor cells in vitro and reduced tumor growth in vivo; overexpression of miR-10b impaired tumor cell elimination through MICB downregulation.\",\n      \"method\": \"3'UTR reporter assays, miRNA mimic/inhibitor, flow cytometry for MICB surface expression, in vitro and in vivo NK cytotoxicity assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — 3'UTR targeting validated with reporters, functional NK killing confirmed in vitro and in vivo, multiple orthogonal methods\",\n      \"pmids\": [\"22915757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ADAM15 mediates MICB ectodomain shedding in pancreatic cancer cells; knockdown of ADAM15 increases cell surface MICB and reduces soluble MICB in conditioned media; gemcitabine suppresses ADAM15 expression, leading to decreased MICB shedding and increased surface MICB without altering MICB mRNA levels.\",\n      \"method\": \"siRNA knockdown of ADAM15, ELISA for soluble MICB, flow cytometry for surface MICB, RT-PCR for mRNA levels, immunohistochemistry on patient tissue\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA knockdown with multiple readouts linking specific metalloprotease to MICB shedding mechanism, single lab\",\n      \"pmids\": [\"23314034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HBsAg overexpression in hepatoma cells induces cellular miRNAs that directly repress MICA and MICB expression via their 3'UTRs, reducing surface MICA/B and decreasing NK cell-mediated cytolysis of HCC cells.\",\n      \"method\": \"miRNA profiling, 3'UTR reporter assays, miRNA inhibitor experiments, flow cytometry, NK cytotoxicity assays\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple miRNAs validated with 3'UTR reporters and functional NK killing assays, single lab\",\n      \"pmids\": [\"23917076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Six RNA-binding proteins (RBPs) bind and regulate MICB expression; at least two RBPs function during genotoxic stress; RBP binding was identified through unbiased RNA pull-down combined with mass spectrometry, establishing post-transcriptional regulation of MICB by RBPs.\",\n      \"method\": \"RNA pull-down assay, mass spectrometry, functional validation of RBP knockdown on MICB expression, genotoxic stress conditions\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — unbiased proteomics approach with functional follow-up, identification of multiple regulators with mechanistic validation\",\n      \"pmids\": [\"24924487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Valproic acid (HDAC inhibitor) upregulates MICA and MICB expression on pancreatic cancer cells via the PI3K/Akt signaling pathway; this effect is blocked by PI3K inhibitor LY294002 or PI3K siRNA, and enhances NK cell-mediated cytotoxicity both in vitro and in vivo.\",\n      \"method\": \"Flow cytometry, qRT-PCR, PI3K inhibitor/siRNA epistasis, xenograft mouse model NK cytotoxicity assays\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological epistasis placing MICB regulation downstream of PI3K/Akt, confirmed in vivo\",\n      \"pmids\": [\"24885711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The RNA-binding protein IMP3 indirectly targets MICB expression through a mechanism functionally distinct from its direct interaction with ULBP2 mRNA (which causes transcript destabilization); IMP3-mediated regulation of MICB leads to impaired NK cell recognition of transformed cells.\",\n      \"method\": \"RIP assay, mRNA stability assays, IMP3 knockdown/overexpression, flow cytometry, NK cell cytotoxicity assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple approaches demonstrating indirect post-transcriptional regulation mechanism, with functional NK cell readout\",\n      \"pmids\": [\"26982091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Vigilin, an RNA-binding protein, binds to the 5'UTR of MICB mRNA and negatively regulates MICB expression; vigilin downregulation in target cells increases MICB surface expression and significantly enhances NK cell activation against those cells.\",\n      \"method\": \"RNA pull-down assay, mass spectrometry, RNAi knockdown of vigilin, flow cytometry for MICB, NK activation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNA pull-down identifies binding, functional consequence measured by NK activation, 5'UTR mechanism demonstrated\",\n      \"pmids\": [\"28356383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ADAM17 (activated by ADAM17) mediates shedding of MICB, MICA, and ULBP2 from AML cell surfaces; hypomethylating agents (AZA, DAC) increase TIMP3 expression by demethylating the TIMP3 gene, and TIMP3 (an ADAM17 inhibitor) reduces soluble MICB shedding, thereby enhancing NKG2D-mediated NK cell recognition.\",\n      \"method\": \"ADAM17 inhibition, TIMP3 siRNA knockdown, bisulfite sequencing, ELISA for soluble MICB, flow cytometry for NKG2D receptor, NK cytotoxicity assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — identifies specific metalloprotease (ADAM17) and its endogenous inhibitor (TIMP3) as mechanism, validated with multiple methods including genetic and pharmacological approaches\",\n      \"pmids\": [\"28404876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"STAT3 inhibition by STA21 increases cell surface MICB expression and soluble MICB secretion from gastric adenocarcinoma cells; recombinant soluble MICB decreases NKG2D receptor levels on NK and CD8+ T cells, impairing their cytolytic activity.\",\n      \"method\": \"STA21 pharmacological inhibition, flow cytometry, ELISA for soluble MICB, NKG2D receptor expression, NK cytotoxicity assays\",\n      \"journal\": \"Immunobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — STAT3 inhibition with functional readouts, but shedding mechanism not fully characterized mechanistically\",\n      \"pmids\": [\"28578917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Antibodies targeting the MICB/MICA alpha3 domain prevent proteolytic shedding of MICA and MICB from human cancer cells, maintaining surface expression; this inhibits tumor growth in immunocompetent mouse models primarily through NK cell activation via NKG2D and CD16 Fc receptors.\",\n      \"method\": \"Antibody engineering, cell surface MICA/B quantification, multiple syngeneic mouse tumor models, NK cell depletion experiments\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple mouse models with mechanistic dissection of NK cell pathway and receptor involvement, high citation count\",\n      \"pmids\": [\"29599246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"miR-34a has a dual role in MICB regulation: it upregulates ATR kinase (promoting MICB expression) and downregulates E2F1 transcription factor (reducing MICB expression); the net effect on MICB depends on endogenous E2F1 levels, with miR-34a promoting MICB expression in cells with low E2F1.\",\n      \"method\": \"miR-34a overexpression/inhibition, ATR and E2F1 protein expression analysis, MICB flow cytometry, NK cell cytotoxicity assays\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — identifies dual regulatory mechanism through two intermediaries, with functional NK cell readout\",\n      \"pmids\": [\"30256916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MG132 (proteasome inhibitor) selectively upregulates MICB transcription in A549 lung cancer cells via the DNA damage response, specifically through activation of ATM kinase and Chk2 phosphorylation; MG132 increases MICB promoter activity (~1.77-fold) and this is blocked by ATM kinase inhibitor KU-55933.\",\n      \"method\": \"Luciferase promoter reporter assay, ATM inhibitor epistasis, Chk2 phosphorylation western blot, flow cytometry, NK cytotoxicity assays\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter reporter assays with inhibitor epistasis establishing DNA damage pathway placement\",\n      \"pmids\": [\"30483783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LXR (Liver X Receptor) activation regulates MICA and MICB expression through distinct mechanisms: MICA is regulated at the transcriptional level (enhanced mica promoter activity), whereas MICB is regulated by inhibiting its lysosomal degradation; both effects increase surface MICA/B and render multiple myeloma cells more susceptible to NK cell killing.\",\n      \"method\": \"Promoter reporter assays for MICA, lysosomal pathway inhibitors for MICB, flow cytometry, NK degranulation and killing assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — distinct mechanisms for MICA vs MICB demonstrated with multiple assays, single lab\",\n      \"pmids\": [\"31125275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HDAC inhibitor panobinostat and anti-MICA/B antibody (blocking shedding) synergistically enhance MICB surface expression on tumor cells: panobinostat enhances MICB gene expression, while the antibody stabilizes synthesized protein on the cell surface; the combination reduces pulmonary metastases in humanized NK cell mouse models.\",\n      \"method\": \"Drug combination assays, flow cytometry, MICB mRNA/protein quantification, humanized NOD/SCID gamma mouse model with human NK cells\",\n      \"journal\": \"Cancer immunology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistically dissects two complementary pathways (transcription vs. shedding) with in vivo validation\",\n      \"pmids\": [\"32209637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Allelic MICB polymorphisms differentially affect binding to HCMV UL16 protein; MICB*008 (containing methionine at position 98 and asparagine at position 113 in the alpha2 domain) shows decreased binding to UL16 compared to MICB*003, *004, and *00502 (containing isoleucine at 98 and aspartic acid at 113), suggesting MICB*008 may be a protective allele for HCMV immune surveillance.\",\n      \"method\": \"Flow cytometry binding assay using soluble Fc-fusion UL16 proteins and stable cell lines expressing specific MICB alleles\",\n      \"journal\": \"Journal of microbiology (Seoul, Korea)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding measurements with allelic cell lines, identifies specific amino acid positions responsible for differential UL16 binding\",\n      \"pmids\": [\"23625227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Transgenic mice ubiquitously expressing human MICB show transient neonatal skin hyperkeratosis with epidermal hyperkeratosis, thickened granular layer, and mild inflammatory cell infiltration in the dermis, as well as ~50% leukocytosis, demonstrating an in vivo role for MICB in skin inflammation.\",\n      \"method\": \"Transgenic mouse generation with ubiquitous MICB promoter, histopathological analysis of skin, blood cell counting\",\n      \"journal\": \"Tissue antigens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transgenic model with histopathological phenotypic readout, two independent transgenic lines confirm phenotype\",\n      \"pmids\": [\"12753668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A common missense MICB variant (MICBD136N) results in reduced surface MICB expression and reduced NKG2D ligation; cells expressing MICBD136N are less susceptible to NK cell killing, and coculture with NK cells shows less NKG2D activation; in clinical cohorts, MICB variant homozygosity is associated with reduced severity of acute lung injury.\",\n      \"method\": \"Missense variant protein expression in cultured cells, flow cytometry for surface MICB, NK cell coculture cytotoxicity, BAL NK cell characterization in human subjects, clinical cohort analysis\",\n      \"journal\": \"American journal of respiratory and critical care medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional validation of specific variant in vitro (surface expression, NKG2D ligation, NK killing) confirmed across two independent clinical cohorts\",\n      \"pmids\": [\"37878820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MICB amino acid position 98 (MICB98) is a key polymorphic residue involved in UL16 binding; mismatches at MICB98 in unrelated-donor hematopoietic cell transplantation are associated with increased acute and chronic GVHD and higher CMV infection/reactivation, establishing MICB98 as a functionally critical position linking UL16 interaction to clinical immune outcomes.\",\n      \"method\": \"Retrospective clinical study of 943 HCT pairs, MICB98 genotyping, hazard ratio analysis for GVHD and CMV outcomes\",\n      \"journal\": \"Bone marrow transplantation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — large clinical cohort with specific amino acid position identified, but functional mechanism derived from prior structural knowledge rather than direct experiment in this paper\",\n      \"pmids\": [\"32286503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Linc-ROR promotes ubiquitination and degradation of RXRA (retinoid X receptor alpha) via E3 ligase UBE4B, reducing RXRA availability; since RXRA is a transcription factor for MICB, its degradation leads to reduced MICB surface expression and impaired NK cell-mediated cytotoxicity against gastric cancer cells.\",\n      \"method\": \"Co-transfection, ubiquitination assays, Linc-ROR overexpression, RXRA protein quantification, flow cytometry for surface MICB, NK-92 cell coculture cytotoxicity assays\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — establishes Linc-ROR → UBE4B → RXRA ubiquitination → MICB reduction pathway with multiple assays\",\n      \"pmids\": [\"38205878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Novel miRNAs binding to both the 3'UTR and 5'UTR of MICB mRNA reduce MICB expression; mutation of miRNA binding sites in either UTR restores luciferase activity in reporter assays; overexpression of candidate miRNAs reduces and inhibition increases MICB protein surface expression.\",\n      \"method\": \"Luciferase reporter assays with MICB 3'UTR and 5'UTR constructs, miRNA mimic/inhibitor experiments, flow cytometry\",\n      \"journal\": \"Genes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — 5'UTR and 3'UTR reporter assays with mutagenesis confirming binding sites and protein-level effects, single lab\",\n      \"pmids\": [\"28850101\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MICB is a stress-induced MHC class I-related surface glycoprotein that acts as a ligand for the NKG2D activating receptor on NK cells, gamma-delta T cells, and CD8+ T cells; its expression is regulated transcriptionally (via NF-Y, Sp1, STAT3, RXRA, and chromatin remodeling) and post-transcriptionally (via cellular and viral miRNAs targeting both 3'UTR and 5'UTR, and RNA-binding proteins including vigilin and IMP3), and is induced by DNA damage through ATM/ATR kinase signaling; surface MICB is shed by metalloproteases (including ADAM15 and ADAM17), with TIMP3 serving as an endogenous inhibitor of shedding; the UL16 protein of HCMV retains MICB intracellularly by binding to its platform domain alpha-helical surface at a site dependent on glutamine-169, and this interaction is allele-dependent (MICB*008/MICBD136N showing reduced binding); at the immunological synapse, MICB drives NKG2D clustering and undergoes bidirectional receptor-ligand transfer that attenuates subsequent NK cell cytotoxicity.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MICB is a stress-induced MHC class I-related surface glycoprotein that serves as a ligand for the NKG2D activating receptor, triggering cytotoxic responses by NK cells, γδ T cells, and CD8+ T cells against transformed and infected cells [PMID:10359807, PMID:11491531]. MICB expression is controlled at multiple levels: transcriptionally by NF-Y, Sp1, STAT3, and RXRA through a polymorphic promoter whose activity is modulated by chromatin remodeling via histone acetylation and DNA methylation [PMID:17557375, PMID:17625602, PMID:18395517, PMID:29]; post-transcriptionally by cellular and viral miRNAs targeting both the 3′UTR and 5′UTR, and by RNA-binding proteins including vigilin and IMP3 [PMID:19380116, PMID:28850101, PMID:28356383, PMID:26982091]; and at the protein level by metalloprotease-mediated ectodomain shedding (ADAM15, ADAM17) counteracted by the endogenous inhibitor TIMP3 [PMID:16698441, PMID:23314034, PMID:28404876]. MICB induction is linked to the DNA damage response through ATM/ATR–Chk1/Chk2 signaling [PMID:18644891, PMID:30483783], and surface MICB is targeted for immune evasion by herpesvirus proteins such as HCMV UL16, which binds the MICB platform domain at a glutamine-169-dependent site to retain it intracellularly, with allelic variation at positions 98 and 113 modulating this interaction [PMID:20090832, PMID:23625227]. A common MICB missense variant (D136N) reduces surface expression and NKG2D-mediated NK killing and is associated with reduced acute lung injury severity [PMID:37878820].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Establishing that MICB functions as a stress-induced antigen recognized by γδ T cells resolved the question of how innate-like lymphocytes detect transformed cells independently of classical peptide–MHC presentation.\",\n      \"evidence\": \"Cytotoxicity assays with Vδ1 γδ T cell lines against autologous and heterologous tumors expressing MICA/B\",\n      \"pmids\": [\"10359807\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"NKG2D had not yet been identified as the receptor\", \"mechanism of stress-induced MICB upregulation unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrating that NKG2D homodimers directly bind monomeric MICA/MICB in solution defined the receptor–ligand pair and revealed that allelic polymorphism at position 129 in the α2 domain governs binding affinity.\",\n      \"evidence\": \"Solution binding assays with soluble NKG2D and MICA, cell surface binding with MICB, allelic mutagenesis\",\n      \"pmids\": [\"11491531\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of NKG2D–MICB interaction not yet resolved\", \"downstream signaling consequences of affinity differences not explored\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Transgenic expression of human MICB in mice producing skin hyperkeratosis and leukocytosis provided the first in vivo evidence that MICB drives inflammatory tissue responses.\",\n      \"evidence\": \"Transgenic mice with ubiquitous MICB expression, histopathology and blood cell counts in two independent lines\",\n      \"pmids\": [\"12753668\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether phenotype is NKG2D-dependent was not tested\", \"relevance to endogenous stress-induced expression levels uncertain\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Two studies established that surface MICB undergoes metalloprotease-mediated shedding to produce a soluble form and that MICB engagement at the NK immunological synapse drives NKG2D clustering, bidirectional receptor–ligand transfer, and subsequent attenuation of NK cytotoxicity.\",\n      \"evidence\": \"Metalloprotease inhibitor experiments with ELISA/flow cytometry for shedding; live-cell imaging and cytotoxicity assays for synapse dynamics\",\n      \"pmids\": [\"16698441\", \"16849432\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the specific sheddase(s) not yet determined\", \"relative contribution of shedding vs. trogocytosis to immune evasion unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Characterization of the MICB promoter identified NF-Y (CCAAT box) and Sp1 (GC box) as essential transcription factors and revealed that a natural 2-bp deletion polymorphism causes an 18-fold reduction in promoter activity, while HDAC inhibition upregulates MICB via increased histone H3 acetylation at the promoter.\",\n      \"evidence\": \"Luciferase reporter/EMSA for promoter elements; ChIP for histone acetylation and HDAC1 occupancy at MICB promoter in leukemic cells\",\n      \"pmids\": [\"17557375\", \"17625602\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of the promoter polymorphism not established\", \"full set of transcription factors regulating MICB promoter not mapped\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Placing MICB induction downstream of ATM/ATR–Chk1 DNA damage signaling—demonstrated via Dicer knockdown and 5-aza-dC treatment with kinase inhibitor epistasis—established the DNA damage response as a central pathway for MICB upregulation.\",\n      \"evidence\": \"Pharmacological and genetic inhibition of ATM/ATR/Chk1, bisulfite sequencing for DNA methylation, flow cytometry and RT-PCR\",\n      \"pmids\": [\"18644891\", \"18395517\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcription factor linking ATM/ATR to MICB promoter activation not identified\", \"contribution of DNA demethylation vs. damage signaling not fully separated\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery that miRNAs from three divergent herpesviruses (HCMV, KSHV, EBV) convergently target the MICB 3′UTR to suppress expression revealed a conserved viral immune evasion strategy operating at the post-transcriptional level.\",\n      \"evidence\": \"3′UTR reporter assays with mutagenesis, miRNA mimics/inhibitors, authentic viral infection, NK cytotoxicity assays\",\n      \"pmids\": [\"19380116\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full repertoire of cellular miRNAs targeting MICB not known\", \"quantitative contribution of miRNA-mediated suppression relative to other evasion mechanisms unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"The 1.8 Å crystal structure of HCMV UL16 bound to MICB revealed that UL16 mimics NKG2D binding geometry on the MICB platform domain and that glutamine-169 is the critical determinant for UL16 engagement, explaining why MICA (arginine-169) escapes UL16 retention.\",\n      \"evidence\": \"X-ray crystallography, surface plasmon resonance, site-directed mutagenesis\",\n      \"pmids\": [\"20090832\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How UL16 retains MICB intracellularly (trafficking mechanism) not resolved\", \"structure of UL16–MICB in membrane context unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of ADAM15 as a MICB sheddase and of allelic variation at MICB positions 98 and 113 as determinants of UL16 binding specificity provided molecular explanations for differential immune evasion across MICB alleles.\",\n      \"evidence\": \"siRNA knockdown of ADAM15 with surface/soluble MICB quantification; Fc-fusion UL16 binding to MICB allelic cell lines\",\n      \"pmids\": [\"23314034\", \"23625227\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contributions of ADAM15 vs. other ADAMs to shedding in different tissues not determined\", \"MICB allele-specific UL16 binding not validated structurally\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Unbiased RNA pull-down/mass spectrometry identified six RNA-binding proteins regulating MICB, at least two functioning during genotoxic stress, establishing post-transcriptional control as a major regulatory axis beyond miRNAs.\",\n      \"evidence\": \"RNA pull-down with MICB UTRs, mass spectrometry, RBP knockdown with MICB expression readout under genotoxic stress\",\n      \"pmids\": [\"24924487\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise binding sites and mechanism for most identified RBPs not characterized\", \"whether RBPs and miRNAs act cooperatively or redundantly unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Three discoveries refined the post-transcriptional and post-translational regulation of MICB: vigilin was identified as a 5′UTR-binding repressor, ADAM17 was shown to be the principal sheddase inhibitable by TIMP3, and novel miRNAs targeting both the 3′UTR and 5′UTR were validated.\",\n      \"evidence\": \"RNA pull-down/MS for vigilin; ADAM17 inhibition and TIMP3 siRNA with shedding assays; luciferase reporters with UTR mutagenesis\",\n      \"pmids\": [\"28356383\", \"28404876\", \"28850101\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis for vigilin–5′UTR interaction unknown\", \"relative importance of ADAM15 vs. ADAM17 across cell types not compared\", \"functional redundancy among UTR-targeting miRNAs not assessed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Antibodies targeting the MICA/MICB α3 domain that block proteolytic shedding demonstrated therapeutic proof-of-concept by maintaining surface NKG2D ligand density and inhibiting tumor growth through NK cell activation via NKG2D and CD16.\",\n      \"evidence\": \"Antibody engineering, surface MICA/B quantification, multiple syngeneic mouse tumor models with NK depletion\",\n      \"pmids\": [\"29599246\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether anti-shedding antibodies affect MICB and MICA equally not fully resolved\", \"contribution of adaptive immune components beyond NK cells not characterized\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A common MICB missense variant (D136N) was shown to reduce surface expression and NKG2D-mediated NK killing, with clinical validation linking homozygosity to reduced acute lung injury severity, directly connecting MICB genetic variation to human disease outcomes.\",\n      \"evidence\": \"Variant protein expression in cells, flow cytometry, NK coculture, two independent clinical cohorts\",\n      \"pmids\": [\"37878820\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for D136N effect on surface expression unknown\", \"whether D136N also affects UL16 or other viral immunoevasin binding not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"The lncRNA Linc-ROR was found to suppress MICB by promoting UBE4B-mediated ubiquitination and degradation of the transcription factor RXRA, adding a new upstream regulatory layer to MICB transcriptional control.\",\n      \"evidence\": \"Co-transfection, ubiquitination assays, RXRA protein quantification, flow cytometry for MICB, NK-92 coculture\",\n      \"pmids\": [\"38205878\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether RXRA binds the MICB promoter directly not demonstrated by ChIP\", \"generalizability beyond gastric cancer cells not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The precise transcription factor cascade linking ATM/ATR activation to MICB promoter induction remains unidentified, and a unified model integrating transcriptional, post-transcriptional (miRNA/RBP), and post-translational (shedding/lysosomal degradation) control of MICB surface density has not been established.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No transcription factor directly connecting ATM/ATR kinase activity to MICB promoter has been identified\", \"Quantitative contributions of shedding, trogocytosis, and miRNA suppression to MICB surface levels in physiological contexts are unknown\", \"Full structural basis of allelic MICB variation on NKG2D vs. viral immunoevasin binding not comprehensively mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 3, 27]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 3, 12, 18, 20, 27]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 3, 8, 20, 27]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [6, 7, 22]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4, 5, 29]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"KLRK1\",\n      \"ADAM17\",\n      \"ADAM15\",\n      \"HDAC1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}